LPAA
NASDAQLaunch One Acquisition Corp.
IPO2024
Launch One Acquisition Corp. (LPAA) is a public company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for LPAA, including 1 press release or news item. The most recent was published Oct 20, 2026.
News · 26 weeks12+100%
2026-05-172026-11-08
Mix390d
- Other2(67%)
- SEC Filings1(33%)
Activity · 52 weeks2417 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
- SECSEC Form 10-Q filed by Launch One Acquisition Corp.10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
- SECLaunch One Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECLaunch One Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events8-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form DEFA14A filed by Launch One Acquisition Corp.DEFA14A - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form 8-K filed by Launch One Acquisition Corp.8-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form DEF 14A filed by Launch One Acquisition Corp.DEF 14A - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form PRER14A filed by Launch One Acquisition Corp.PRER14A - Launch One Acquisition Corp. (0002015502) (Filer)
- INSIDERSEC Form 3 filed by new insider Rogers Daniel C3 - Launch One Acquisition Corp. (0002015502) (Issuer)
- SECSEC Form 8-K filed by Launch One Acquisition Corp.8-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form PRE 14A filed by Launch One Acquisition Corp.PRE 14A - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form 10-Q filed by Launch One Acquisition Corp.10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form 10-K filed by Launch One Acquisition Corp.10-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECSEC Form 425 filed by Launch One Acquisition Corp.425 - Launch One Acquisition Corp. (0002015502) (Subject)
- SECLaunch One Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Launch One Acquisition Corp. (0002015502) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Launch One Acquisition Corp.SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)
- SECSEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
- SECSEC Form SCHEDULE 13G filed by Launch One Acquisition Corp.SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)
- SECSEC Form 425 filed by Launch One Acquisition Corp.425 - Launch One Acquisition Corp. (0002015502) (Subject)
- PRMinovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy PlatformHAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding
- PRMinovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and ExpositionHAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company's mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology's (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-
- SECSEC Form 10-Q filed by Launch One Acquisition Corp.10-Q - Launch One Acquisition Corp. (0002015502) (Filer)
LPAA FAQ
4 questionsWhat is the latest news on LPAA?
In the last 30 days Quantisnow tracked 1 wire item for LPAA: 1 press release or news item. The most recent was published on October 20, 2026.Where does LPAA stock trade?
Launch One Acquisition Corp. (LPAA) is listed on NASDAQ.When did Launch One Acquisition Corp. go public?
Launch One Acquisition Corp. (LPAA) completed its IPO in 2024.How can I track LPAA on Quantisnow?
Quantisnow aggregates Launch One Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LPAA to receive live email and push alerts on every new disclosure.